[go: up one dir, main page]

WO2008108736A1 - Particules pour l'administration de facteurs bioactifs - Google Patents

Particules pour l'administration de facteurs bioactifs Download PDF

Info

Publication number
WO2008108736A1
WO2008108736A1 PCT/SG2007/000065 SG2007000065W WO2008108736A1 WO 2008108736 A1 WO2008108736 A1 WO 2008108736A1 SG 2007000065 W SG2007000065 W SG 2007000065W WO 2008108736 A1 WO2008108736 A1 WO 2008108736A1
Authority
WO
WIPO (PCT)
Prior art keywords
species
binding
microparticle
solution
hydrophilic polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SG2007/000065
Other languages
English (en)
Inventor
Jackie Y Ying
Andrew C A Wan
Benjamin Tai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Priority to PCT/SG2007/000065 priority Critical patent/WO2008108736A1/fr
Publication of WO2008108736A1 publication Critical patent/WO2008108736A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere

Definitions

  • the present invention relates to biodegradable cell-responsive polymer microparticles to s deliver bioactive factors, such as growth factors.
  • the present invention also relates to methods of synthesis of biodegradable cell-responsive polymer microparticles.
  • tissue engineering and regeneration relies on the proper provision of io bioactive factors to the cells that would potentially constitute the new tissue.
  • factors may be in the form of cytokines, growth factors or cell adhesion ligands.
  • the factors may be soluble, tethered to the extracellular matrix (ECM) or localized on the surface membrane of neighbouring cells.
  • ECM extracellular matrix
  • growth factors are immobilized on monolithic polyethylene glycol (PEG)-based hydrogels which are cross-linked with specific oligopeptide or polypeptide sequences, which are susceptible to degradation by matrix metalloproteinases (MMPs) produced by cells, thus delivering the factors in response to0 exposure to cell-derived proteinases.
  • PEG polyethylene glycol
  • MMPs matrix metalloproteinases
  • Bioactive factor may be covalently coupled to the degradable hydrogel matrix, due to the sensitivity of growth factorS activity to the structural modifications required to bind the factor to the matrix.
  • monolithic materials may not be useful in certain applications, such as where the material is provided to the circulation.
  • a microparticle for delivery of a bioactive factor comprising a hydrophilic polymer crosslinked with a crosslinking group, the crosslinking group being degradable by a releasing species produced by a cell, and a binding species coupled to the hydrophilic polymer by a coupling group, the binding species being capable of binding and releasing a bioactive factor, and whereby exposure of the microparticle to the releasing species causes release of the binding species.
  • the hydrophilic polymer may be a polyether.
  • the hydrophilic polymer is branched, such as a branched polyethylene glycol,
  • the crosslinking group may be an oligopeptide or a polypeptide, or an oligosaccharide or polysaccharide.
  • crosslinking group is an oligopeptide or polypeptide, it may be from about 8 to about
  • the releasing species is an endopeptidase.
  • the coupling group is a cysteine residue.
  • the binding species is heparin or a heparin-like molecule.
  • the microparticle has a diameter of between about 200 and 400nm.
  • the microparticles may comprise a bioactive factor bound to the binding species.
  • a process for making microparticles for delivery of a bioactive factor comprising: a) preparing a precursor microparticle comprising a hydrophilic polymer crosslinked with a crosslinking group, said crosslinking group being degradable by a releasing species produced in a cell, and a binding species coupled to the hydrophilic polymer by a coupling group, said binding species being capable of binding the bioactive factor; and b) binding the bioactive factor to the precursor microparticle to produce the microparticles.
  • step a) comprises: al) providing a first solution comprising the hydrophilic polymer in a first solvent, said hydrophilic polymer having terminal groups capable of reacting with a crosslinker., said crosslinker comprising the crosslinking group; a2) providing a second solution comprising the binding species bound to the coupling 5 species in a second solvent; a3) providing a third solution comprising the crosslinker in a third solvent; a4) combining the third solution with a fourth solvent that is immiscible with the first, second and third solvents to form a dispersion; a5) combining the first solution and the second solution, thereby coupling the hydrophilic io polymer to the binding species to form a mixture; a6) combining the mixture and the dispersion to form a reaction mix; and a7) agitating the reaction mix sufficiently to crosslink the hydrophilic polymer and form the precursor microparticles in the fourth solvent.
  • step b) comprises: bl) combining a suspension of the precursor particles in an aqueous solvent with a solution of the bioactive factor in a solvent that is miscible with the aqueous solvent to form a0 binding mixture; and b2) allowing the binding mixture to react for sufficient time for the bioactive factor to bind to the precursor particles.
  • a process for making microparticles for delivery of a bioactive factor comprising: S i) providing a precursor solution comprising a precursor species, said precursor species comprising a hydrophilic polymer, a binding species coupled to the hydrophilic polymer by a coupling group, and the bioactive factor, said bioactive factor being bound to the binding species; and ii) reacting the precursor species with a crosslinker to form the microparticles, said0 crosslinker comprising a crosslinking group which is degradable by a releasing species produced in a cell.
  • step i) comprises: il) providing a first solution comprising the hydrophilic polymer in a first solvent, said hydrophilic polymer having terminal groups capable of reacting with a crosslinker, said 5 crosslinker comprising the crosslinking group; 12) providing a second solution comprising the coupling species bound to the binding species in a second solvent;
  • step ii) comprises: iil) combining the precursor solution with a solution of the crosslinker and agitating the resulting mixture sufficiently to crosslink the precursor species and form the microparticles.
  • Figure 1 is a diagrammatic illustration of the synthesis of cell-responsive particles using Method 1. Binding of growth factor (e.g. FGF-2) in the last step occurs by specific structural and charge interactions with heparin.
  • growth factor e.g. FGF-2
  • FIG 2 is a diagrammatic illustration of the synthesis of cell-responsive particles using Method 2. Binding of growth factor (e.g. FGF-2) occurs by specific structural and charge interactions with heparin in the first step of the reaction.
  • Figure 3 is a diagrammatic representation of the interaction between the components of the cell responsive particles. Proteolytic cleavage of the MMP-degradable crosslinker releases heparin with its bound growth factor from the particle.
  • growth factor e.g. FGF-2
  • Figure 4 illustrates light micrographs of cell-responsive particles prepared by (a) Method 1 and (b) Method 2.
  • the scale bar in (a) is 20 micrometers, and in (b) 200 micrometers.
  • Figure 5 provides a graph which illustrates the concentration of free FGF-2 in solution, as determined by ELISA, after filtration to remove the FGF-2-binding particles. This figure demonstrates that cysteine-heparin is necessary for the binding of FGF-2 to the particle.
  • Figure 6 provides graphs of relative cell numbers (as measured by alamarBlue®) of 3T3 cells cultured with ( ⁇ ) and without ( ⁇ ) particles loaded with (a) 1 ng/ml, (b) 10 ng/ml, and (c) 100 ng/ml of FGF-2.
  • Figure 7 provides a graph of relative cell numbers (as measured by alamarBlue®) of hMSCs cultured in a cell pellet ( ⁇ 1 x 10 5 cells) without particles (•), with particles crosslinked with MMP-degradable peptide with ( ⁇ ) and without ( ⁇ ) 10 ng/ml of FGF-2, and with particles crosslinked with scrambled peptide (to demonstrate that that particle degradation is sequence specific) loaded with 10 ng/ml of FGF-2 ( ⁇ ).
  • Abbreviations as measured by alamarBlue®
  • FGF-2 Fibroblast Growth Factor-2 hMSCs human Mesenchymal Stem Cells
  • PEG-VS poly-(ethylene glycol)-vinyl sulfone
  • the inventors have developed cell-responsive biodegradable microparticles for delivering a bioactive factor.
  • microparticle encompasses discrete particles or loose aggregates of particles, wherein the maximum diameter of the individual particles is from 0.1 ⁇ m to 100 ⁇ m, and more preferably is between 0.2 ⁇ m and 50 ⁇ m, and is intended to exclude monolithic materials.
  • the microparticles provided herein are able to be produced in a range of sizes and morphologies.
  • the microparticles are substantially discrete particles which may be produced in a range of sizes from about 200 nm to about 400 nm as measured by a ZetaPALS particle analyser (Brookhaven Instruments Corporation, New York, NY), by variation of the conditions of particle synthesis, as described below. Particles of this embodiment may be produced by Method 1 described herein. For particles of a particular size, the range of particle sizes may vary by approximately ⁇ 20 nm.
  • the particles may be produced in loose aggregates ranging in size from 40 to 1100 ⁇ m, with the individual particles within the aggregates ranging in size from 1 to 30 ⁇ m.
  • Particles of this embodiment may be produced by Method 2 described herein. Variation of the sizes of the microparticles of both of these embodiments may be achieved through manipulation of the conditions of particle synthesis. Conditions of synthesis which may influence particle size include the concentration of any one or more of the polymer, the crosslinking group and the binding species which are comprised in the particle, the concentration of surfactant used in the synthesis of the particles, and the degree of agitation during the synthesis of the particles.
  • the ratio of surfactant to polymer, the ratio of polymer to crosslinking species and other ratios of the components used in the synthesis may also affect the particle size, and the polydispersity of the particles.
  • the particle size may also be affected by the nature of the surfactant, the charge on the surfactant and other related factors.
  • the particles may be monodispersed or may have a narrow or broad polydispersity. An increase in the agitation during particle formation commonly leads to a decrease in the particle size. Similarly, an increase in the ratio of surfactant to polymer, or to polymer plus crosslinking group, may also lead to a decrease in the particle size.
  • the ratio of molar ratio of functionalized groups on the polymer to coupling group in the synthesis of the microparticles is between about 3 to 1 and 3.5 to 1, for example 3.3 to 1.
  • the molar ratio of functionalized groups on the polymer to corresponding functionalized groups on the crosslinker which bind to the functionalized groups on the polymer is between about 1 to 3 and 1 to 4, for example approximately 1 to 3.56.
  • Microparticles of defined size ranges may be produced from a mixture of microparticles of different sizes by the use of size exclusion membranes, meshes or filters.
  • Nuclear track etched membranes, for example, are readily available in pore sizes ranging from 100 nm to 12 ⁇ m and greater, and may be used to selectively retain particles of a size greater than the selected pore diameter.
  • the cell-responsive biodegradable microparticles described herein may be made from materials which have previously only been described in monolithic form.
  • the present particles comprise a hydrophilic polymer which is crosslinked with a crosslinking group, and a binding species which is capable of binding the bioactive factor.
  • the hydrophilic polymer may comprise small organic gel forming molecules, such as peptides or peptide amphiphiles, which may be assembled into supramolecular structures after crosslinking with a crosslinking group.
  • the hydrophilic polymer is a polyether, such as a polyethylene glycol (PEG). It may be an ethylene oxide propylene oxide copolymer, or a copolymer of ethylene oxide with some other monomer, e.g. with some other polyether monomer.
  • the hydrophilic polymer may have a functionality greater than 2, e.g. 3, 4, 5, 6, 7, 8, 9, 10 or more than 10.
  • the functional groups may be at chain ends. They may be located along the chain. They may be located both at chain ends and along the chain.
  • the polymer may be a branched polymer, and may have 1, 2, 3, 4, 5 or more than 5 branches. It may be a hyperbranched polymer. It may be a starburst dendrimer.
  • the functional groups should be capable of reacting with the crosslinlcing group in order to crosslink the polymer.
  • the functional group may be derived from for example hydroxyl, amino, thiol etc. These may be activated towards reaction with the crosslinker by conversion to, for example, a vinyl sulfone or other activated olefmic group.
  • Suitable features for the polymer include (but are not limited to) that it is substantially biocompatible, non-toxic, resistant to protein adsorption, and substantially inert under the biological conditions to which it will be exposed in use.
  • the polymer may be such that, following crosslinking, it is flexible. It may be capable of forming a hydrogel following crosslinking.
  • the distance between crosslinks may be sufficiently large to provide the desired flexibility and/or water swell. This will vary depending on the nature of the crosslinker and of the polymer, but may be at least about 10 atoms, or at least about 15, 20, 25, 30, 35, 40, 45 or 50 atoms.
  • the distance between crosslinks may be sufficiently small that the polymer when crosslinked is insoluble in water.
  • the distance between crosslinks may be between about 5 and about 100 atoms, or between about 10 and 100, 20 and 100, 50 and 100, 5 and 50, 5 and 20 or 20 and 50 atoms.
  • the molecular weight of the polymer (prior to crosslinking) will depend on the nature of the polymer and on the desired properties of the particles. It may be between about 500 and about 100000, or between about 1000 and 100000, 5000 and 100000, 10000 and 100000, 50000 and 100000, 500 and 50000, 500 and 10000, 500 and 5000, 500 and 1000, 1000 and 100000, 1000 and 10000 or 5000 and 50000, ,e.g.
  • Individual branches of the polymer may have between about 2 and about 100 monomer units, or between about 2 and 50, 2 and 20, 2 and 10, 5 and 100, 10 and 100, 50 and 100, 5 and 50 or 5 and 20, e.g. about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90 or 100 monomer units.
  • the distance between crosslinks in the polymer when crosslinked reflects the distance between functional groups capable of crosslinking in the uncrosslinked polymer.
  • the skilled worker will be able to determine by routine experiment the optimum polymer to be used in order to achieve the desired properties.
  • PEG-based polymers The synthesis of cell-responsive monolithic PEG-based polymers is described in Lutolf and Hubbell (2003) Biomacromolecules 4: 713-722, the entire contents of which are incorporated herein by reference.
  • the present invention provides methods to produce such PEG-based polymers in microparticle form.
  • the PEG may be linear or multiarmed, and in one embodiment at least three armed. It will be understood that although specific polymers are described herein, a person of skill in the art would readily recognise that other hydrophilic polymers having the properties described above could be substituted for the PEG polymers without materially altering the invention, and may be incorporated into the microparticles of the invention as described herein for PEG.
  • the polymer will possess functionalisation which allows interaction with the crosslinker to form a supramolecular structure during particle synthesis.
  • the crosslinker will comprise thiol groups, which may for example be present in cysteine groups in the crosslinker (particularly if the crosslinker is a peptide).
  • the polymer should contain groups which can react with the thiol groups. Suitable groups include olef ⁇ nic groups which are activated towards thiol addition or other Michael addition. They may be electron deficient olef ⁇ nic groups, e.g. vinyl sulfones, acrylates, methacrylates, maleate half esters, maleimido groups etc.
  • an activatable group such as hydroxyl, thiol, amine etc.
  • an activating reagent e.g. vinyl sulfonyl chloride, acryloyl chloride, methacryloyl chloride, maleic anhydride etc.
  • the crosslinking of the polymer with a crosslinking group allows for the formation of supramolecular structures.
  • the crosslinking group also provides a site which may be degraded by a releasing species produced by a cell, such as a matrix metalloproteinase, thereby allowing the release of fragments of the particle comprising the bioactive factor.
  • the crosslinking group will have at least two sites which are independently able to crosslink with a functionality present on polymer molecules, to allow the crosslinking of at least two polymer molecules together.
  • the releasing species may be produced by a mammalian cell, or may be produced by a bacterium, fungus or yeast.
  • the mammalian cell may be a cancer cell.
  • the crosslinking group is an oligopeptide or polypeptide which comprises an amino acid sequence which is cleaved by an enzyme which is secreted by a cell or which is present on the plasma membrane of a cell.
  • Amino acid sequences which provide a cleavage site for the releasing species Plasmin, Stromelysin, Elastase, Collagenase, or the plasminogen activators t-PA and u-PA, and which are suitable for inclusion in a crosslinker are disclosed in US patent serial No. 6, 894,022 (Hubbell et al), the entire contents of which are incorporated by reference.
  • the releasing species will be a cell-associated extracellular endopeptidase, such as a member of the matrix metalloproteinase (MMP) family (IUBMB Enzyme Nomenclature Family EC 3.4.24).
  • MMP matrix metalloproteinase
  • IUBMB Enzyme Nomenclature Family EC 3.4.24 matrix metalloproteinase family
  • matrix metalloproteinases are secreted by or expressed on the surface of cells during cell proliferation, tissue remodelling, angiogenesis and in metastasis and tumour cell invasion of tissues, and accordingly amino acid sequences which are known to be sensitive to cleavage by one or more matrix metalloproteinases are also contemplated.
  • the enzyme-sensitive domain present in the crosslinking group may comprise a naturally occurring amino acid sequence which is a substrate of these enzymes, or it may comprise a synthetic sequence which is recognised and cleaved.
  • the crosslinking group comprises the amino acid sequence GPQGIWGQ (SEQ ID NO:1) which is recognised by several matrix metalloproteinases and which is rapidly cleaved to GPQG (SEQ ID NO:2) and IWGQ (SEQ ID NO:3) by these enzymes.
  • GPQGIWGQ amino acid sequence GPQGIWGQ
  • IWGQ IWGQ
  • the crosslinking group may comprise the amino acid sequence GLPG (SEQ ID NO:4) (Bettio F et al., (2006) Biomacromolecules 7: 3534-3541, the entire contents of which is incorporated herein by reference).
  • the crosslinking group may comprise the amino acid sequence GGLGPAGGK (SEQ ID NO:5).
  • Other amino acid sequences which act as substrates for collagenase and which may be used in a crosslinking group are disclosed in Netzel-Arnett et al. (1991) J Biol Chem 266: 6747- 6755, the entire contents of which is incorporated by reference.
  • the crosslinking group may comprise the amino acid sequence AAAAAAAAAK (SEQ ID NO:6) (Mann B et al., (2001) Biomaterials 22: 3045-3051, the entire contents of which are incorporated herein by reference).
  • crosslinking group is an amino acid sequence
  • the crosslinking group is at least 8, at least 9 or at least 10 amino acids in length to allow for both crosslinking at two sites on the crosslinking group and for at least the minimum amino acid sequence required to be recognised and cleaved by a cell-produced proteinase. While the maximum length of the amino acid sequence of the crosslinking group is less critical, amino acid sequences longer than about 30 amino acids may reduce the density of the particles which may interfere with the particle's structural integrity.
  • the crosslinking group will typically comprise at least two cysteine residues to provide the potential for crosslinking with the vinyl sulfone groups of the macromer by Michael-type addition reactions.
  • the crosslinking group may be functionalized with an amine, alcohol, or any nucleophilic functional group.
  • the crosslinking group may comprise an oligosaccharide or polysaccharide sequence where the releasing species is an enzyme which is directed to polysaccharide cleavage, such as a heparinase, a heparanase, a heparitinase, a chondroitinase or lysozyme.
  • Heparinase I cleaves heparin and heparan sulfate at the linkages between hexosamines and O-sulfated iduronic acids.
  • Heparinase II cleaves heparan sulfate, and to a lesser extent heparin at the 1-4 linkages between hexosamines and uronic acid residues (both glucuronic and iduronic), yielding mainly disaccharides.
  • Heparinase III cleaves at the 1-4 linkages between hexosamine and glucuronic acid residues in heparan sulfate, yielding mainly disaccharides.
  • Heparanase is an endo- ⁇ -D- glucuronidase that catalyzes the hydrolytic cleavage of the ⁇ -l,4-glycosidic bond between a D- glucuronate and a D-glucosamine.
  • Chondroitinase ABC catalyzes the eliminative degradation of polysaccharides containing 1 ,4- ⁇ -D-hexosaminyl and 1,3- ⁇ -D-glucuronosyl or 1,3- ⁇ -L- iduronosyl linkages to disaccharides containing 4-deoxy-b-D-gluc-4-enuronosyl groups.
  • Lysozyme catalyzes the hydrolysis of 1,4- ⁇ -linkages between N-acetylmuramic acid and N- acetyl-D-glucosamine residues in a peptidoglycan and between N-acetyl-D-glucosamine residues in chitodextrins. Accordingly, the incorporation of relevant saccharide residues in the crosslinking group to render the crosslinking group sensitive to cleavage by any one or more of these enzymes is contemplated.
  • the microparticles comprise a binding species which is coupled to the polymer by a coupling group.
  • the binding species provides a site to non-covalently releasably bind a bioactive factor, thus allowing the bioactive factor to be incorporated into the particles in a manner which mimics the binding of a bioactive factor under physiological conditions.
  • the binding species is heparin or a heparin-like molecule such as a synthetic heparin or a heparan sulphate.
  • the heparin or heparin-like molecule may be bound to one or more of the other components of the crosslinked polymer by covalent or non-covalent methods.
  • the heparin On release from the microparticle, the heparin may then carry and present the bioactive factor to a cell in a manner which mimics the heparin-mediated presentation of bioactive factors in situ.
  • the heparin may be coupled by functionalizing it with cysteine residues, allowing the heparin to interact with vinyl sulfone functionalization or other suitable functionalization (e.g. acrylate, acrylamide, maleic half ester, maleimido) on the polymer by a Michael-type addition reaction.
  • heparin may be coupled to the polymer by carbodiimide coupling of heparin to amino-terminated PEG.
  • the heparin may be coupled to the polymer via amide linkages on the polymer and -COOH groups on heparin, via activated carbonates, thiocarbonates and so on (e.g.
  • Suitable click chemistry may include for example cycloaddition reactions, such as the Huisgen 1,3 -dipolar cycloaddition, Cu(I) catalyzed azide-acetylene cycloaddition, Diels-Alder reaction, nucleophilic substitution to small strained rings (e.g. epoxy and aziridine rings), formation of ureas and amides and addition reactions to double bonds, e.g. epoxidation, dihydroxylation.
  • cycloaddition reactions such as the Huisgen 1,3 -dipolar cycloaddition, Cu(I) catalyzed azide-acetylene cycloaddition, Diels-Alder reaction, nucleophilic substitution to small strained rings (e.g. epoxy and aziridine rings), formation of ureas and amides and addition reactions to double bonds, e.g. epoxidation, dihydroxylation.
  • heparin-like factors as binding species, such as other glycosaminoglycans including heparan sulphate, hyaluronic acid, dermatan sulphate, chondroitin-4 and -6 sulphates, and keratan sulphates, or synthetic heparin as binding species is also contemplated.
  • bioactive factors have been demonstrated to bind heparin.
  • growth factors such as basic and acidic FGF, members of the TGF- ⁇ superfamily including bone morphogenic proteins, interleukin-8, neurotrophin-6, heparin-binding epidermal growth factor, hepatocyte growth factor, connective tissue growth factor, midkine, heparin-binding growth associated molecule and members of the vascular endothelial growth factor (VEGF) family.
  • VEGF vascular endothelial growth factor
  • a growth factor will be considered to be heparin-binding if it elutes from a heparin-affinity column at NaCl concentrations above physiological levels (greater than or equal to 140 mM). It will also be understood that numerous bioactive factors bind to heparin-like molecules, and accordingly the delivery of bioactive factors which bind heparin-like molecules is also contemplated.
  • bioactive factors may be used with the particles described herein. These bioactive factors may be inherently able to bind heparin non-covalently, such as fibronectin, neural cell adhesion molecule and anti thrombin III.
  • bioactive factors including growth factors
  • Exemplary heparin binding peptide sequences are described in US patent serial No. 6,894,022 (supra).
  • Heparin binding amino acid sequences derived from anti-thombin III, platelet factor-4, neural cell adhesion molecule, fibronectin, basic or acid fibroblast growth factor or lipoprotein lipase, for example may be incorporated into a bioactive factor using techniques described in US patent serial No. 6,894,022 (supra), for example by the creation of a fusion protein.
  • heparin in addition to the advantageous properties of heparin in non-covalently sequestering and delivering bioactive factors, the inventors have observed that incorporation of heparin as a binding agent during the synthesis of the microparticles unexpectedly stabilised the microparticles.
  • the binding species may also be Type II pro-collagen (which binds TGF- ⁇ l and BMP-2), a pentosan polysulfate, phosphorothioate oligodeoxynucleotides or synthetic heparin analogues.
  • microparticles may be used to deliver bioactive factors in a wide variety of circumstances.
  • the microparticles may find use in the same applications as other slow release delivery systems in delivery of therapeutic agents, growth factors and the like, and in addition may be used as an alternative to monolithic cell responsive materials.
  • the microparticles may be conveniently incorporated into matrices of biological or synthetic origin for tissue engineering applications, or they may be incorporated onto the surface of implantable materials to regulate the initial interactions between the implantable material and the surrounding tissue.
  • bioactive factor may be selected from amongst a wide range of molecules, both naturally occurring and synthetic. These include trophic factors, immunomodulatory factors, cytokines, factors which stimulate or inhibit the formation of scar tissue, factors which stimulate or inhibit new vessel formation, cytotoxic or cytostatic agents directed toward neoplastic cells, adhesion factors and factors which guide cell migration.
  • the present invention provides two processes for making the microparticles described herein.
  • the first process comprises the steps of: a) preparing a precursor microparticle comprising a hydrophilic polymer crosslinked with a crosslinking group, said crosslinking group being degradable by a releasing species produced in a cell, and a binding species coupled to the hydrophilic polymer by a coupling group, said binding species being capable of binding the bioactive factor; and then b) binding the bioactive factor to the precursor microparticle to produce the microparticles.
  • Step a) may comprise the following steps: al) providing a first solution comprising the hydrophilic polymer in a first solvent, said hydrophilic polymer having terminal groups capable of reacting with a crosslinker, said crosslinker comprising the crosslinking group; a2) providing a second solution comprising the binding species bound to the coupling species in a second solvent; a3) providing a third solution comprising the crosslinker in a third solvent; a4) combining the third solution with a fourth solvent that is immiscible with the first, second and third solvents to form a dispersion; a5) combining the first solution and the second solution, thereby coupling the hydrophilic polymer to the binding species to form a mixture; a6) combining the mixture and the dispersion to form a reaction mix; and a7) agitating the reaction mix sufficiently to crosslink the hydrophilic polymer and form the precursor microparticles in the fourth solvent.
  • the hydrophilic polymer may be a PEG polymer, e.g. a branched PEG, although other polymers as earlier described may be used.
  • a suitable polymer is a 4-arm PEG.
  • the polymer should be functionalised with, for example, olefinic groups activated towards Michael addition.
  • the first solution may be between about 10 and about 50mg/ml in polymer, e.g. between about 30 and 40mg/ml, depending on the degree of functionalisation and molecular weight of the polymer.
  • the solution is commonly an aqueous solution and may comprise a buffer.
  • the buffer may be sufficient to maintain the pH of the solution at between about 5.5 and about 6.5, e.g. about 6.0.
  • the solution will also comprise a surfactant.
  • the surfactant may be a non-ionic surfactant. It may be an alkylphenyl ethoxylate surfactant.
  • the surfactant may be present in a concentration of up to about 0.1% by weight, e.g. between about 0.01 and 0.1 %, for example about 0.05% by weight.
  • the second process comprises the steps of: i) providing a precursor solution comprising a precursor species, said precursor species comprising a hydrophilic polymer, a binding species coupled to the hydrophilic polymer by a coupling group, and the bioactive factor, said bioactive factor being bound to the binding species; and ii) reacting the precursor species with a crosslinker to form the microparticles, said crosslinker comprising a crosslinking group which is degradable by a releasing species produced in a cell.
  • Step i) may comprise
  • step ii) may comprise the step of combining the precursor solution with a solution of the crosslinker and agitating the resulting mixture sufficiently to crosslink the precursor species and form the microparticles.
  • Method 1 Two methods were employed to prepare the cell-responsive particles with bound growth factor.
  • growth factor was added to the particles in the final step, i.e. after the particles had been synthesized.
  • Method 2 growth factor was added during the particle synthesis process, in the first step where heparin binding of the growth factor was allowed to take place.
  • the sequence of reagent addition for particle synthesis is illustrated diagrammatically in Figure 1 for Method 1 and in Figure 2 for Method 2.
  • Hubbell (2003, supra).
  • the modified method utilised a different reaction pH, a surfactant and a non-polar solvent to obtain microparticles through micelle formation.
  • the commercial sources of the reagents were as follows: 4-arm PEG (Molecular Weight 20 kDa; OH-terminated, NEKTAR), Divinyl Sulfone (Merck), TEOA (Fluka), L-cysteine monohydrate hydrochloride (Merck), and Heparin Sodium Salt from porcine intestinal mucosa (SIGMA, H-9399).
  • heparin The cysteine functionalisation of heparin was modified from Bernkop-Schniirch et ah, (2001) J. Control. Release 71: 277. Briefly, a 1 % (w/v) solution of heparin (Sigma; (Ci 4 H 38 NiO 36 Ss) n , monomer m/wt 1090.87) was prepared in deionized water. l-ethyl-3-(3- dimethylaminopropyl)carbodiimide (EDC, Merck) was added to the heparin solution in a final concentration of 50 niM and reacted for 45 minutes.
  • EDC l-ethyl-3-(3- dimethylaminopropyl)carbodiimide
  • Cysteine-heparin was purified by dialyzing (Spectrum Laboratories, MWCO 3500) the mixture against 1 mM HCl for 1 hour at 4 °C. This was followed by dialysis twice against 1 mM HCl containing 1 % (w/v) sodium chloride (NaCl, Merck) for 1 hour each at 4 °C and, finally, overnight against 1 mM HCl at 4°C. The purified product was isolated by lyophilization (VirTis BenchTop 4K Freeze Dryer). This synthesis produced a degree of substitution of between 300 and 700 ⁇ mol cysteine/gram of product.
  • PEG-VS 4-arm PEG-vinyl sulfone (33.2 mg/ml) as synthesized by the method of Lutolf and Hubbell (2003, supra) and cysteine-heparin (8.62 mg/ml) were prepared in triethanolamine (TEOA) buffer (pH 6.0) containing 0.05% (v/v) Triton-X 100 (Sigma).
  • TEOA triethanolamine
  • a solution of the MMP -2 and plasmin-sensitive peptide crosslinker GCRDGPQGIWGQDRCG (SEQ ID NO:7) (66.67 mg/ml, GenScript Corporation) was also prepared in TEOA buffer (pH 6.0). As described in Lutolf and Hubbell (2003 supra), this peptide was chosen due to its sensitivity to MMPs and its rapid degradation kinetics.
  • a scrambled peptide GCRDGDQGIAGFDRCG (SEQ ID NO:8) was used as a control to investigate whether degradation of the particles and the resultant release of growth factors was dependent on specific protease activity, rather than as a result of a non-specific hydrolysis.
  • the reactions between the 4-arm PEG-VS and the peptide cross-linker and cysteine- functionalized heparin are based on Michael addition of thiols (from cysteine) to vinyl sulfone.
  • 24.2 ⁇ l of the 4-arm PEG-VS solution were mixed with 11.2 ⁇ l of the cysteine-heparin solution, which provided a molar ratio of VS groups in the 4-arm PEG-VS to Cysteine (in cysteine- heparin) of approximately 3.33 to 1.
  • the mixture was then added to a dispersion of 7.5 ⁇ l of the peptide cross-linker solution in 500 ⁇ l of dichloromethane (providing a molar ratio of VS groups (in 4-arm PEG-VS) to cysteine (in the peptide cross linker) of approximately 1 to 3.56).
  • concentrations of reagents used above were determined empirically using a series of varying concentrations of reactants and a model peptide to determine which concentrations produced microparticles.
  • the mixture was vortexed in a sealed microcentrifuge tube at a speed setting of 4 to 5 overnight (Scientific Industries Vortex Genie 2) to form an emulsion.
  • the organic phase (dichloromethane) was evaporated to isolate the particles which were formed, and 200 ⁇ l of deionized water was added to the remaining mixture.
  • the resulting particle dispersion was transferred to a centrifugal filter (Whatman UF 10OkD), and centrifuged at 1000 rpm and 4°C for 30 min. The remaining particles were then dispersed in 200 ⁇ l of deionized water, and rinsed by centrifugation under similar conditions. Finally, the isolated particles were dispersed by tituration in 200 ⁇ l of deionized water and stored for further use.
  • the particle dispersion was mixed with a known concentration of a growth factor solution (1, 10 or 100 ng/ml of human Fibroblast Growth Factor-2 (FGF-2, R&D Systems), or 10 or 100 ng/ml of recombinant mouse Stromal Derived Factor- 1 (SDF-I, R&D Systems), and incubated for 1 hour with mild shaking on an orbital shaker to bind growth factor to the particles.
  • a growth factor solution 1, 10 or 100 ng/ml of human Fibroblast Growth Factor-2 (FGF-2, R&D Systems), or 10 or 100 ng/ml of recombinant mouse Stromal Derived Factor- 1 (SDF-I, R&D Systems)
  • the post-synthetic addition of the bioactive factor allows the bioactive factor to be added shortly before when the microparticles are intended for use, thereby minimising any loss of bioactivity of the factor due to storage.
  • a second method growth factor was added in the first step of the particle synthesis process where heparin-binding of the growth factor was allowed to take place.
  • the synthesis of cell-responsive particles according to Method 2 proceeded as follows.
  • a solution of 4-arm PEG- VS (33.2 mg/ml) and cysteine-heparin (8.62 mg/ml) were prepared in TEOA buffer (pH 6.0) containing 0.05% (v/v) Triton-X as described for Method 1.
  • a solution of the peptide crosslinker GCRDGPQGIWGQDRCG (66.67 mg/ml) (SEQ ID NO:7) was also prepared in TEOA buffer (pH 6.0) as described for Method 1.
  • Particle size distributions were obtained using a ZetaPALS zeta potential analyzer (Brookhaven Instruments Corporation, New York, NY). Method 1 yielded discrete particles which were 200-400 nm ( Figure 4a). Method 2 tended to generate larger aggregates of particles ( Figure 4b). To investigate the requirement of cysteine-heparin in the microparticles to bind the bioactive factor, two sets of microparticles were synthesised according to Method 1, with one set of particles synthesised without cysteine-heparin and another with cysteine-heparin.
  • the concentration of free growth factor was monitored in the supernatant by ELISA as described above at each step of the reaction to investigate whether the growth factor was bound to the particles formed, thereby resulting in a drop in the detected concentration of free growth factor.
  • the results of this analysis are presented in Table 1.
  • growth factor loaded particles 50 ⁇ l 100ng/ml FGF-2 mixed with 50 ⁇ l of particle suspension
  • Method 2 were exposed to plasmin from human plasma (7.5 ⁇ g/ml, Sigma) in tris- buffered saline pH 7.4 .
  • 5 ⁇ l of plasmin solution was incubated with 50 ⁇ l of particle suspension for 24 hours at room temperature.
  • the protein factors were released upon plasmin treatment, as detailed in Table 2.
  • Two cell culture configurations were used to investigate the effect of FGF-loaded cell- responsive particles on the proliferation of the mouse fibroblast cell line (NIH-3T3, ATCC) and human mesenchymal stem cells (hMSCs, Cambrex).
  • a transwell culture configuration the particles are physically separated from the cells, but diffusion is possible between the cells and particles. This assay is relevant to examine the where the particles were used for therapeutic purposes.
  • a pellet culture system where the cells and particles are cultured in close proximity, is useful for studying the effect of the particles on tissue development, including spatial effects within the pellet. Such a system is comparable to the "neo-tissues" used for concomitant delivery of growth factors and cells to the brain.
  • a suspension of 2000 cells and 66.67 ⁇ l of particles (particle suspension prepared according to Method 2 and pre-loaded with 0, 1, 10 or 100ng/ml of FGF-2) and media (to a total of 700 ⁇ l) were placed into a well in a 24-well plate.
  • a transwell insert (Nunc) was then placed into each well and filled with 400 ⁇ l of tissue culture media. Cells were then incubated for 2 to 3 weeks, and cell viability assessed using alamarBlue ® assay. The results are presented in Figure 6.
  • % reduction in Figure 6 refers to the percentage of the cell viability marker, alamarBlue ® , which was reduced from the blue to the red form, indicating the relative number of viable cells, i.e. the higher the % reduction, the greater the number of viable cells.
  • heparin binding sites were presumably not saturated with growth factor, allowing the heparin to bind and present other factors present in the serum, such as TGF- ⁇ .
  • Cells were cultured in DMEM with 10% fetal bovine serum (FBS). These other factors could provide more potent proliferative signals compared to the bound FGF-2.
  • FBS fetal bovine serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des microparticules biodégradables sensibles aux cellules, comprenant un polymère hydrophile réticulé au moyen d'un groupe de réticulation qui est dégradable par une espèce de libération produite par une cellule, et une espèce de liaison couplée au polymère pour la liaison et l'administration d'un facteur bioactif, tel qu'un facteur de croissance, à une cellule. L'invention concerne également des procédés de synthèse de microparticules biodégradables sensibles aux cellules.
PCT/SG2007/000065 2007-03-06 2007-03-06 Particules pour l'administration de facteurs bioactifs Ceased WO2008108736A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/SG2007/000065 WO2008108736A1 (fr) 2007-03-06 2007-03-06 Particules pour l'administration de facteurs bioactifs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SG2007/000065 WO2008108736A1 (fr) 2007-03-06 2007-03-06 Particules pour l'administration de facteurs bioactifs

Publications (1)

Publication Number Publication Date
WO2008108736A1 true WO2008108736A1 (fr) 2008-09-12

Family

ID=39738514

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SG2007/000065 Ceased WO2008108736A1 (fr) 2007-03-06 2007-03-06 Particules pour l'administration de facteurs bioactifs

Country Status (1)

Country Link
WO (1) WO2008108736A1 (fr)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060485A1 (fr) 2008-11-28 2010-06-03 Zetascience Gmbh Hydrogel bioactif
US8034396B2 (en) 2008-04-01 2011-10-11 Tyco Healthcare Group Lp Bioadhesive composition formed using click chemistry
US8512728B2 (en) 2009-02-21 2013-08-20 Sofradim Production Method of forming a medical device on biological tissue
US8535477B2 (en) 2009-02-21 2013-09-17 Sofradim Production Medical devices incorporating functional adhesives
US8648144B2 (en) 2009-02-21 2014-02-11 Sofradim Production Crosslinked fibers and method of making same by extrusion
US8663689B2 (en) 2009-02-21 2014-03-04 Sofradim Production Functionalized adhesive medical gel
US8795331B2 (en) 2010-03-25 2014-08-05 Covidien Lp Medical devices incorporating functional adhesives
US8846099B2 (en) 2008-08-05 2014-09-30 Coretherapix, Slu Parenteral composition comprising microspheres with a diameter between 10 and 20 microns
US8865857B2 (en) 2010-07-01 2014-10-21 Sofradim Production Medical device with predefined activated cellular integration
US8877170B2 (en) 2009-02-21 2014-11-04 Sofradim Production Medical device with inflammatory response-reducing coating
US8956603B2 (en) 2009-02-21 2015-02-17 Sofradim Production Amphiphilic compounds and self-assembling compositions made therefrom
US8968818B2 (en) 2009-02-21 2015-03-03 Covidien Lp Medical devices having activated surfaces
US8968733B2 (en) 2009-02-21 2015-03-03 Sofradim Production Functionalized surgical adhesives
US8969473B2 (en) 2009-02-21 2015-03-03 Sofradim Production Compounds and medical devices activated with solvophobic linkers
US9039979B2 (en) 2009-02-21 2015-05-26 Sofradim Production Apparatus and method of reacting polymers passing through metal ion chelated resin matrix to produce injectable medical devices
US9247931B2 (en) 2010-06-29 2016-02-02 Covidien Lp Microwave-powered reactor and method for in situ forming implants
US9272074B2 (en) 2010-03-25 2016-03-01 Sofradim Production Surgical fasteners and methods for sealing wounds
US9273191B2 (en) 2009-02-21 2016-03-01 Sofradim Production Medical devices with an activated coating
WO2016044836A1 (fr) * 2014-09-19 2016-03-24 Board Of Regents, The University Of Texas System Microgels obtenus par génie génétique
US9375699B2 (en) 2009-02-21 2016-06-28 Sofradim Production Apparatus and method of reacting polymers by exposure to UV radiation to produce injectable medical devices
US9523159B2 (en) 2009-02-21 2016-12-20 Covidien Lp Crosslinked fibers and method of making same using UV radiation
US9555154B2 (en) 2009-02-21 2017-01-31 Covidien Lp Medical devices having activated surfaces
WO2017040200A1 (fr) * 2015-08-28 2017-03-09 The Regents Of The University Of Michigan Dispositif d'immunoisolation
US9775928B2 (en) 2013-06-18 2017-10-03 Covidien Lp Adhesive barbed filament
US9987297B2 (en) 2010-07-27 2018-06-05 Sofradim Production Polymeric fibers having tissue reactive members

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894022B1 (en) * 1998-08-27 2005-05-17 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894022B1 (en) * 1998-08-27 2005-05-17 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIM S.H. ET AL.: "PEG conjugated VEGF siRNA for anti-angiogenic gene therapy", JOURNAL OF CONTROLLED RELEASE, vol. 116, 2006, pages 123 - 129, XP005794264 *
KIM T.H. ET AL.: "Pegylated recombinant human epidermal growth factor (rhEGF) for sustained release from biodegradable PLGA microspheres", BIOMATERIALS, vol. 23, 2002, pages 2311 - 2317, XP004345260 *

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034396B2 (en) 2008-04-01 2011-10-11 Tyco Healthcare Group Lp Bioadhesive composition formed using click chemistry
US8846099B2 (en) 2008-08-05 2014-09-30 Coretherapix, Slu Parenteral composition comprising microspheres with a diameter between 10 and 20 microns
WO2010060485A1 (fr) 2008-11-28 2010-06-03 Zetascience Gmbh Hydrogel bioactif
US8859706B2 (en) 2008-11-28 2014-10-14 Zetascience Gmbh Bioactive hydrogel
US10632207B2 (en) 2009-02-21 2020-04-28 Sofradim Production Compounds and medical devices activated with solvophobic linkers
US9039979B2 (en) 2009-02-21 2015-05-26 Sofradim Production Apparatus and method of reacting polymers passing through metal ion chelated resin matrix to produce injectable medical devices
US9523159B2 (en) 2009-02-21 2016-12-20 Covidien Lp Crosslinked fibers and method of making same using UV radiation
US8648144B2 (en) 2009-02-21 2014-02-11 Sofradim Production Crosslinked fibers and method of making same by extrusion
US8535477B2 (en) 2009-02-21 2013-09-17 Sofradim Production Medical devices incorporating functional adhesives
US10167371B2 (en) 2009-02-21 2019-01-01 Covidien Lp Medical devices having activated surfaces
US8877170B2 (en) 2009-02-21 2014-11-04 Sofradim Production Medical device with inflammatory response-reducing coating
US8956603B2 (en) 2009-02-21 2015-02-17 Sofradim Production Amphiphilic compounds and self-assembling compositions made therefrom
US8968818B2 (en) 2009-02-21 2015-03-03 Covidien Lp Medical devices having activated surfaces
US8968733B2 (en) 2009-02-21 2015-03-03 Sofradim Production Functionalized surgical adhesives
US8969473B2 (en) 2009-02-21 2015-03-03 Sofradim Production Compounds and medical devices activated with solvophobic linkers
US8663689B2 (en) 2009-02-21 2014-03-04 Sofradim Production Functionalized adhesive medical gel
US9216226B2 (en) 2009-02-21 2015-12-22 Sofradim Production Compounds and medical devices activated with solvophobic linkers
US9555154B2 (en) 2009-02-21 2017-01-31 Covidien Lp Medical devices having activated surfaces
US8512728B2 (en) 2009-02-21 2013-08-20 Sofradim Production Method of forming a medical device on biological tissue
US9273191B2 (en) 2009-02-21 2016-03-01 Sofradim Production Medical devices with an activated coating
US9550164B2 (en) 2009-02-21 2017-01-24 Sofradim Production Apparatus and method of reacting polymers passing through metal ion chelated resin matrix to produce injectable medical devices
US9375699B2 (en) 2009-02-21 2016-06-28 Sofradim Production Apparatus and method of reacting polymers by exposure to UV radiation to produce injectable medical devices
US9421296B2 (en) 2009-02-21 2016-08-23 Covidien Lp Crosslinked fibers and method of making same by extrusion
US9511175B2 (en) 2009-02-21 2016-12-06 Sofradim Production Medical devices with an activated coating
US9510810B2 (en) 2009-02-21 2016-12-06 Sofradim Production Medical devices incorporating functional adhesives
US9517291B2 (en) 2009-02-21 2016-12-13 Covidien Lp Medical devices having activated surfaces
US9272074B2 (en) 2010-03-25 2016-03-01 Sofradim Production Surgical fasteners and methods for sealing wounds
US9554782B2 (en) 2010-03-25 2017-01-31 Covidien Lp Medical devices incorporating functional adhesives
US10143471B2 (en) 2010-03-25 2018-12-04 Sofradim Production Surgical fasteners and methods for sealing wounds
US8795331B2 (en) 2010-03-25 2014-08-05 Covidien Lp Medical devices incorporating functional adhesives
US9247931B2 (en) 2010-06-29 2016-02-02 Covidien Lp Microwave-powered reactor and method for in situ forming implants
US8865857B2 (en) 2010-07-01 2014-10-21 Sofradim Production Medical device with predefined activated cellular integration
US9987297B2 (en) 2010-07-27 2018-06-05 Sofradim Production Polymeric fibers having tissue reactive members
US9775928B2 (en) 2013-06-18 2017-10-03 Covidien Lp Adhesive barbed filament
WO2016044836A1 (fr) * 2014-09-19 2016-03-24 Board Of Regents, The University Of Texas System Microgels obtenus par génie génétique
WO2017040200A1 (fr) * 2015-08-28 2017-03-09 The Regents Of The University Of Michigan Dispositif d'immunoisolation
US10918673B2 (en) 2015-08-28 2021-02-16 The Regents Of The University Of Michigan Immunoisolation device
US11786560B2 (en) 2015-08-28 2023-10-17 The Regents Of The University Of Michigan Immunoisolation device

Similar Documents

Publication Publication Date Title
WO2008108736A1 (fr) Particules pour l'administration de facteurs bioactifs
Freudenberg et al. Glycosaminoglycan‐based biohybrid hydrogels: a sweet and smart choice for multifunctional biomaterials
US6565842B1 (en) Crosslinkable polypeptide compositions
JP4954370B2 (ja) 共役不飽和基に対する求核付加反応によって作製される生体適合材料
Jeon et al. Affinity-based growth factor delivery using biodegradable, photocrosslinked heparin-alginate hydrogels
Linhardt et al. Immobilization of heparin: approaches and applications
AU622699B2 (en) Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
Baldwin et al. Polysaccharide‐modified synthetic polymeric biomaterials
Xu et al. Hyaluronic acid-based hydrogels: from a natural polysaccharide to complex networks
Bae et al. Injectable biodegradable hydrogels: progress and challenges
KR100314488B1 (ko) 다당류겔조성물
US5041292A (en) Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
EP2106263B1 (fr) Dérivés réactifs solubles dans l'eau de carboxy polysaccharides et conjugués à base de carboxy polysaccharides et du fibrinogène
EP4151661A1 (fr) Compositions d'hydrogel à base d'alginate
KR101522462B1 (ko) 효소 고정화 지지체를 이용한 in situ 형성 하이드로젤의 제조방법 및 이의 생의학적 용도
ES2492891T3 (es) Carboxipolisacáridos activados químicamente y usos
EP1781335A2 (fr) Hydrogel conjugé polymèrique d'une prodrogue
JP2003535066A (ja) 薬学的活性化合物の制御された送達のための共役付加反応
CN102740862A (zh) 具有内源性带电配体的水解淀粉微球
WO2015168090A1 (fr) Hydrogels dégradables multimodes pour la libération contrôlée de substances de chargement
KR102437315B1 (ko) 하이브리드 하이드로겔 및 이의 생의학적 용도
Patil et al. Crosslinking of polysaccharides: methods and applications
US20130084278A1 (en) Water soluble reactive derivatives of carboxy polysaccharides and fibrinogen conjugates thereof
KR101920284B1 (ko) 성장인자의 서방형 전달을 위한 헤파린 나노스폰지 및 이의 제조방법
Vlcek et al. Enzymatic Degradation of Glycosaminoglycans and Proteoglycan-Mimetic Materials in Solution and on Polyelectrolyte Multilayer Surfaces

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07716154

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07716154

Country of ref document: EP

Kind code of ref document: A1